Sandhya Prashad
Psychiatry · Houston, TXNPI 1821237991
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $102,023 of the $157,365 with a category attached, or 64.8%. Johnson & Johnson accounts for 94.4% of it on its own, with 19 other manufacturers making up the rest. Reporting peaked in 2019 at $90,420 and has fallen 97.6% since, to $2,139 in 2025. Among psychiatry clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 728 payments — averaging $216.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$149K
- AbbVie$1K
- Otsuka America Pharmaceutical, Inc.$1K
- Bausch Health US, LLC$1K
- Brainsway USA Inc$1K
- Lundbeck LLC$1K
- plus $3K from 14 others
What the payments were for
- Consulting fees$12,8608%
- Speaking & faculty fees$102,02365%
- Travel & lodging$27,73518%
- Food & beverage$14,7259%
- Education$220%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 292 | $148,506 |
| AbbVie(2 entities) | 71 | $1,276 |
| Otsuka America Pharmaceutical, Inc. | 65 | $1,228 |
| Bausch Health US, LLC | 84 | $1,197 |
| Brainsway USA Inc | 1 | $1,174 |
| Lundbeck LLC | 61 | $1,130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 45 | $754 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 30 | $589 |
| Vanda Pharmaceuticals Inc. | 22 | $385 |
| Eisai Inc. | 13 | $280 |
| Corium, LLC | 12 | $220 |
| Sunovion Pharmaceuticals Inc. | 12 | $218 |
| Noven Therapeutics, LLC | 6 | $98 |
| Axsome Therapeutics, Inc. | 3 | $70 |
| Adlon Therapeutics L.p. | 4 | $67 |
| Almatica Pharma LLC | 2 | $57 |
| Janssen Scientific Affairs, LLC | 1 | $47 |
| Shire North American Group Inc | 2 | $38 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Ironshore Pharmaceuticals Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$157,365 in reported general payments places this provider in the 95th percentile of 2,238 psychiatry providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Venlafaxine Hcl ErVenlafaxine Hcl | 22 | $600 |
| Buspirone Hcl | 26 | $458 |
| Lamotrigine | 13 | $299 |
| Trazodone Hcl | 29 | $278 |
| Duloxetine Hcl | 16 | $241 |
| Quetiapine Fumarate | 14 | $220 |
| Gabapentin | 13 | $192 |
| Temazepam | 12 | $111 |
Paid to pharmacies, not to this prescriber.
Other psychiatry in Houston
- Matthew BramsHouston$1.5M
- Frank ChenHouston$941K
- Alice MaoHouston$850K
- Mazhar KhowajaHouston$843K
- Barry GritzHouston$792K
- Aaron PetersonHouston$700K
- Ayesha RashidHouston$641K
- Lawrence GinsbergHouston$502K
- Kathy FlanaganHouston$443K
- Rayan Al JurdiHouston$359K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.